ECMOFOBIA, porque 14 picadelas por dia deixam qualquer um ecmofóbico...

quinta-feira, 20 de julho de 2017



Parvus is pioneering a breakthrough class of disease-specific biological therapeutics called NavacimsTM that are designed to halt and potentially cure autoimmune disease by restoring immune tolerance. The Company’s robust therapeutic platform is capable of generating a rich pipeline of therapeutic candidates for a wide range of autoimmune diseases. Parvus has validated two lead drug candidates to take into clinical development for Type 1 diabetes (T1D) and Multiple Sclerosis (MS), and is scaling up drug product manufacture for GLP toxicology studies.

Sem comentários:

Enviar um comentário